Royalty Pharma (RPRX) Operating Expenses (2019 - 2026)

Royalty Pharma has reported Operating Expenses for 8 years, with the latest figure at $67.5 million in Q1 2026.

• Quarterly Operating Expenses rose 98.26% year-over-year to $67.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $852.1 million (up 134.46% YoY) and the FY2025 annual result came in at $818.7 million, down 15.7% from the prior year.
• Operating Expenses eased to $67.5 million in Q1 2026 per RPRX's latest filing, from $233.6 million in the prior quarter.
• Over five years, Operating Expenses peaked at $1.0 billion in Q4 2022 and troughed at -$170.4 million in Q3 2024.
• A 5-year average of $273.5 million and a median of $233.6 million in 2025 frame the typical range for Operating Expenses.
• The widest YoY moves for Operating Expenses: up 1479.41% in 2024, down 144.27% in 2024.
• Over 5 years, Operating Expenses stood at $1.0 billion in 2022, then tumbled by 101.61% to -$16.8 million in 2023, then soared by 1479.41% to $232.1 million in 2024, then increased by 0.64% to $233.6 million in 2025, then slumped by 71.09% to $67.5 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $67.5 million, $233.6 million, and $182.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.